Compare Citius Pharmaceuticals Inc (CTXR) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Iovance Biotherapeutics Inc. Common Stock trades at $14.19 (market cap $6.04B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 443.5× Citius Pharmaceuticals Inc's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| CTXR | IOVA | |
|---|---|---|
Market Cap | $13.62M | $6.04B |
Volume | 132,438 | 14,805,993 |
Sector | Health | Health |
52-Week High | $1.82 | $14.82 |
52-Week Low | $0.48 | $1.81 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $3.79M | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
